Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism
about
New investigational drugs with single-agent activity in multiple myelomaMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsTargeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein HomeostasisSynergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanismsMCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancersCyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivoMultiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activityDinaciclib for the treatment of breast cancer.A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress.Novel investigational drugs active as single agents in multiple myeloma.Overview of CDK9 as a target in cancer research.Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma.Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.The therapeutic potential of cell cycle targeting in multiple myeloma.LX2343 alleviates cognitive impairments in AD model rats by inhibiting oxidative stress-induced neuronal apoptosis and tauopathy.Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen.
P2860
Q28071551-C2BDA184-81DD-4A1C-9943-2DDCA64A6DBEQ28075606-827A0F33-069D-4994-8496-2D55E9184291Q28269674-DDCE5DAC-E607-45DB-A643-BC340DF33177Q33761796-24618CA7-B50C-47DA-A556-E326A6A0158AQ34301314-2C440D36-8B09-499D-B025-F1D22D5B4E2EQ34706060-C24ADDE6-2B53-47AE-B13B-7AA2823A6C15Q36020882-86831A60-4931-4CFD-94A0-CBAFC3F4E6F8Q36072490-A9145275-F47C-4D45-A7E7-15D8CACD3529Q37063908-9A17218B-0E00-449E-BBFA-61A8DD444AD1Q38238282-C75C7D6C-B22C-422E-A8D2-80844DDD8338Q38239644-15BDA921-AF0D-4412-A8E8-EBCCB51236DBQ38690290-AECD8224-13B4-40D7-88E8-913061998F4AQ38696353-D1E8C8A6-FCCC-42E3-B023-53C01291C1C5Q40063670-36005049-EEA3-4E8D-A7C5-21D1E9FE2123Q41708707-B50E0A4D-0EEF-4410-B831-E87A04B2C470Q46640442-43E98B5F-F66A-4DF2-A781-8542E74428B3Q47203904-75B5021D-89D6-4F50-861D-999742BB91CBQ47993126-348EE768-514C-47FB-B774-596304025F33Q48125728-33481393-722D-4194-91E4-B9AE83AE17CF
P2860
Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Dinaciclib (SCH727965) inhibit ...... DK1- and 5-dependent mechanism
@ast
Dinaciclib (SCH727965) inhibit ...... DK1- and 5-dependent mechanism
@en
Dinaciclib
@nl
type
label
Dinaciclib (SCH727965) inhibit ...... DK1- and 5-dependent mechanism
@ast
Dinaciclib (SCH727965) inhibit ...... DK1- and 5-dependent mechanism
@en
Dinaciclib
@nl
prefLabel
Dinaciclib (SCH727965) inhibit ...... DK1- and 5-dependent mechanism
@ast
Dinaciclib (SCH727965) inhibit ...... DK1- and 5-dependent mechanism
@en
Dinaciclib
@nl
P2860
P1476
Dinaciclib (SCH727965) inhibit ...... DK1- and 5-dependent mechanism
@en
P2093
Steven Grant
Tri K Nguyen
P2860
P304
P356
10.1158/1535-7163.MCT-13-0714
P577
2013-12-20T00:00:00Z